1Fuchs CS,Mayer RJ.Gastric carcinoma.N Engl J Med 1995;333 (1):32-41.
2Wong JE,Ito Y,Correa P et al.Therapeutic strategies in gastric cancer.J Clin Oncol 2003; 21 (23 Suppl):267s-9s.
3Yeh KH,Shun CT,Chen CL et al.High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy.Cancer 1998; 82 (9):1626-31.
4Kelsen D,Atiq OT,Sahz L et al.FAMTX versus etoposide,doxorubicin,and cisplatin:a random assignment trial in gastric cancer.J Clin Oncol 1992; 10 (4):541-8.
5Takeno S,Noguehi T,Kikuchi R et al.Analysis of the survival period in resectable stage Ⅳ gastric cancer.Ann Surg Oncol 2001;8(3):215-21.
6Danenberg PV.Thymidylate synthetase-a target enzyme in cancer chemotherapy.Biochim Biophys Acta 1977; 473 (2):73-92.
7Greta JL,Quinn M,Ismail AS et al.Pharmacokinetics and pharmacodynamic effects of 5-fluomuracil given as a one-hour intravenous infusion.Cancer Chemother Pharmacol 2001;47 (2):117-25.
8Peters GJ,van der Wilt CL,van Triest B et al.Thymidylate synthase and drug resistance.Eur J Cancer 1995; 31A (7-8):1299-305.
9Wang FS,Aschele C,Sobrero A et al.Decreased folylpelyglutamate synthetase expression:a novel mechanism of fluorouracil resistance.Cancer Res 1993; 53 (16):3677-80.
10Chu E,Voeller DM,Morrison PF et al.The effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA.J Biol Chem 1994; 269 (32):20289-93.
